Antipsychotic Use in Pregnancy: Patient Mental Health Challenges, Teratogenicity, Pregnancy Complications, and Postnatal Risks

Pregnant women constitute a vulnerable population, with 25.3% of pregnant women classified as suffering from a psychiatric disorder. Since childbearing age typically aligns with the onset of mental health disorders, it is of utmost importance to consider the effects that antipsychotic drugs have on pregnant women and their developing fetus. However, the induction of pharmacological treatment during pregnancy may pose significant risks to the developing fetus. Antipsychotics are typically introduced when the nonpharmacologic approaches fail to produce desired effects or when the risks outweigh the benefits from continuing without treatment or the risks from exposing the fetus to medication. Early studies of pregnant women with schizophrenia showed an increase in perinatal malformations and deaths among their newborns. Similar to schizophrenia, women with bipolar disorder have an increased risk of relapse in antepartum and postpartum periods. It is known that antipsychotic medications can readily cross the placenta, and exposure to antipsychotic medication during pregnancy is associated with potential teratogenicity. Potential risks associated with antipsychotic use in pregnant women include congenital abnormalities, preterm birth, and metabolic disturbance, which could potentially lead to abnormal fetal growth. The complex decision-making process for treating psychosis in pregnant women must evaluate the risks and benefits of antipsychotic drugs

Rimegepant for the treatment of migraine.

Migraine is a common form of primary headache, affecting up to 1 in every 6 Americans. The pathophysiology is an intricate interplay of genetic factors and environmental influence and is still being elucidated in ongoing studies. The trigeminovascular system is now known to have a significant role in the initiation of migraines, including the release of pain mediators such as CGRP and substance P. Traditional treatment of migraine is usually divided into acute and preventive treatment. Acute therapy includes non-specific therapy, such as NSAIDs and other analgesics, which may provide relief in mild to moderate migraines. 5-HT1 agonists may provide relief in severe migraine, but are not universally effective and carry a significant side-effect profile with frequent redosing requirement. Prophylactic therapy may reduce the occurrence of acute migraine attacks in selected patients, but does not completely eliminate it. More recently, CGRP antagonism has been studied and shown to be effective in both abortion and prevention of migraine. Novel medications, targeting CGRP, divide into CGRP antibodies and receptor antagonists (gepants). Rimegepant, a second-generation gepant, has shown efficacy in several clinical trials in treating acute migraine. Ongoing trials are also evaluating its role in migraine prophylaxis, and results are promising. It is also generally safer for use than existing options, does not appear to increase the chance of developing chronic migraines, and carries a very tolerable side effects profile. It is a part of a growing arsenal in migraine treatment, and may present the silver bullet for treatment of this disease

Wave farm impact on the beach profile: A case study

If wave energy is to become a fully-fledged renewable, its environmental impacts must be fully understood. The objective of the present work is to examine the impact of a wave farm on the beach profile through a case study. The methodology is based on two coupled numerical models: a nearshore wave propagation model and a morphodynamic model, which are run in two scenarios, both with and without the wave farm. Wave data from a nearby coastal buoy are used to prescribe the boundary conditions. A positive effect on the wave climate, the cross-shore sediment transport and, consequently, the evolution of the beach profile itself due to the presence of the wave farm was found. The wave farm leads to a reduction in the erosion of the beach face. This work constitutes the first stage of the investigation of the effectiveness of a wave farm as a coastal defence measure, and the accuracy of the quantification of the erosion reduction will be enhanced in future research. In any case, the overarching picture that emerges is that wave farms, in addition to providing carbon-free energy, can be used as elements of a coastal defence scheme.If wave energy is to become a fully-fledged renewable, its environmental impacts must be fully understood. The objective of the present work is to examine the impact of a wave farm on the beach profile through a case study. The methodology is based on two coupled numerical models: a nearshore wave propagation model and a morphodynamic model, which are run in two scenarios, both with and without the wave farm. Wave data from a nearby coastal buoy are used to prescribe the boundary conditions. A positive effect on the wave climate, the cross-shore sediment transport and, consequently, the evolution of the beach profile itself due to the presence of the wave farm was found. The wave farm leads to a reduction in the erosion of the beach face. This work constitutes the first stage of the investigation of the effectiveness of a wave farm as a coastal defence measure, and the accuracy of the quantification of the erosion reduction will be enhanced in future research. In any case, the overarching picture that emerges is that wave farms, in addition to providing carbon-free energy, can be used as elements of a coastal defence scheme

Factored MDP Elicitation and Plan Display

The software suite we will demonstrate at AAAI ’06 was designed around planning with factored Markov decision processes (MDPs). It is a user-friendly suite that facilitates domain elicitation, preference elicitation, planning, and MDP policy display. The demo will concentrate on user interactions for domain experts and those for whom plans are made

Brexanolone to Treat Postpartum Depression in Adult Women.

ZULRESSO (Brexanolone) is a novel FDA-approved treatment for moderate-to-severe postpartum depression. Postpartum depression may be diagnosed in women experiencing depressive symptoms which can manifest as cognitive, behavioral, or emotional disturbances as early as the third trimester to 4 weeks following delivery. The efficacy of brexanolone suggests that neurosteroids such as allopregnanolone are important to treat PPD. However, it is currently unclear if brexanolone provides lasting relief of depressive symptoms at or beyond 30 days following administration. Further studies are necessary to make this determination